[{"address1": "Three International Towers", "address2": "Level 24 300 Barangaroo Avenue", "city": "Sydney", "state": "NSW", "zip": "2000", "country": "Australia", "phone": "61 2 9472 4101", "website": "https://www.kaziatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. John Edwin Friend II, M.D.", "age": 53, "title": "CEO, MD & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 744028, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gabrielle  Heaton BBUS (ACC), CPA", "title": "Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer", "fiscalYear": 2023, "totalPay": 181715, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anna  Sandham", "title": "Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.192, "open": 0.3, "dayLow": 0.27, "dayHigh": 1.08, "regularMarketPreviousClose": 0.192, "regularMarketOpen": 0.3, "regularMarketDayLow": 0.27, "regularMarketDayHigh": 1.08, "beta": 2.131, "volume": 430245029, "regularMarketVolume": 430245029, "averageVolume": 7486629, "averageVolume10days": 44693090, "averageDailyVolume10Day": 44693090, "bid": 0.6038, "ask": 0.6433, "bidSize": 400, "askSize": 600, "marketCap": 19907950, "fiftyTwoWeekLow": 0.19, "fiftyTwoWeekHigh": 1.15, "priceToSalesTrailing12Months": 35549.91, "fiftyDayAverage": 0.2674, "twoHundredDayAverage": 0.4154, "currency": "USD", "enterpriseValue": 172944528, "floatShares": 234362035, "sharesOutstanding": 29793400, "sharesShort": 23749, "sharesShortPriorMonth": 48178, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0008, "heldPercentInstitutions": 0.109960005, "shortRatio": 0.15, "impliedSharesOutstanding": 23634900, "bookValue": 0.2, "priceToBook": 3.341, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -15702666, "trailingEps": -0.38, "lastSplitFactor": "1:4", "lastSplitDate": 1499990400, "enterpriseToRevenue": 308829.53, "enterpriseToEbitda": -9.869, "52WeekChange": -0.24719101, "SandP52WeekChange": 0.24919295, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "KZIA", "underlyingSymbol": "KZIA", "shortName": "Kazia Therapeutics Limited", "longName": "Kazia Therapeutics Limited", "firstTradeDateEpochUtc": 915633000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "1898cad7-893e-3eb8-a2ff-3751c401090e", "messageBoardId": "finmb_401773", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6682, "targetHighPrice": 2.05, "targetLowPrice": 2.05, "targetMeanPrice": 2.05, "targetMedianPrice": 2.05, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 3562602, "totalCashPerShare": 0.014, "ebitda": -17524020, "totalDebt": 359300, "quickRatio": 0.32, "currentRatio": 0.706, "totalRevenue": 560, "debtToEquity": 6.821, "returnOnAssets": -0.46423, "returnOnEquity": -1.86374, "freeCashflow": -6574324, "operatingCashflow": -12684881, "grossMargins": 1.0, "operatingMargins": -1480567.4, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-07-11"}]